세계의 바이러스학 검사 시장 예측(-2030년) : 제품 유형별, 방법별, 진단 기술별, 방법별, 용도별, 최종사용자별, 지역별 분석

According to Stratistics MRC, the Global Virology Testing Market is accounted for $12.7 billion in 2023 and is expected to reach $16.4 billion by 2030 growing at a CAGR of 3.8% during the forecast period. Virology testing refers to the diagnostic processes and laboratory techniques used to detect, identify, and study viruses in biological samples. These tests help identify the presence of specific viruses, determine the type and strain of the virus, and assess the immune response to viral infections. Moreover, virology testing assists in determining the most effective antiviral treatments for infected individuals, contributing to personalized medicine approaches to managing viral diseases. Virology testing is essential in screening blood donations for the presence of blood-borne viruses such as HIV, hepatitis B, and hepatitis C, ensuring the safety of blood transfusions.

According to the World Health Organization (WHO), in 2021, 60% of the global population was suffering from infectious diseases.

Market Dynamics:

Driver:

Rising prevalence of viral infections

The increasing prevalence of viral infections worldwide is a significant driver for the growth of the virology testing market. The persistent emergence of infectious diseases, including influenza, HIV, hepatitis, and, more recently, the global COVID-19 pandemic, has heightened the demand for accurate and timely diagnostic solutions. As viral infections continue to pose significant public health challenges, there is a pressing need for advanced virology testing methods that can swiftly identify and differentiate various viruses. Moreover, virology testing plays a pivotal role in disease surveillance, aiding healthcare professionals in making informed decisions regarding treatment, containment measures, and public health interventions.

Restraint:

High cost

The high cost of virology tests is a significant restraint in the virology testing market, impacting accessibility and affordability for both healthcare providers and patients. Advanced virology testing methods, particularly molecular diagnostic techniques like PCR (Polymerase Chain Reaction) and next-generation sequencing, often involve expensive reagents, equipment, and skilled personnel. The financial burden associated with virology testing may lead to delays in testing, inadequate surveillance, and underreporting of viral infections. Moreover, it could impede the development of robust public health strategies, hindering the ability to effectively control and manage viral outbreaks.

Opportunity:

Technological advancements

In the virology testing market, technological advancements have revolutionized diagnostic capabilities, enhancing the precision and efficiency of virus detection. Polymerase chain reaction (PCR) techniques have undergone significant refinements, enabling the rapid and accurate identification of viral genetic material. Furthermore, the development of innovative point-of-care testing devices has facilitated quicker and more decentralized diagnostics, particularly during pandemics. Automation and robotics have streamlined laboratory workflows, reducing turnaround times and enhancing testing throughput. These technological strides not only contribute to the early and precise diagnosis of viral infections but also play a pivotal role in global health by supporting surveillance efforts and bolstering pandemic preparedness.

Threat:

Antibiotic resistance

Antibiotic resistance is a critical concern within the virology testing market, albeit indirectly. Virology testing primarily focuses on identifying and diagnosing viral infections, which are not treated with antibiotics. However, the issue arises in clinical practice when patients with viral infections are mistakenly prescribed antibiotics. The misuse and overuse of antibiotics contribute to the development of antibiotic resistance, a phenomenon where bacteria evolve to withstand the effects of these medications. If virology tests are not employed effectively to identify the viral nature of an infection, antibiotics may be unnecessarily prescribed. This mismanagement fuels antibiotic resistance, posing a broader threat to public health.

COVID-19 Impact

The COVID-19 pandemic has profoundly impacted the virology testing market, triggering unprecedented demand for diagnostic solutions worldwide. The urgent need for large-scale testing to identify and contain the spread of the virus has led to a surge in the adoption of various virology testing methods, including PCR assays, antigen tests, and serological tests. This increased demand has prompted rapid innovation and the development of new testing technologies.

The cell culture method segment is expected to be the largest during the forecast period

The cell culture method segment is estimated to hold the largest share. The cell culture method is a fundamental and indispensable technique in virology testing, playing a pivotal role in the isolation, propagation, and study of viruses. The process involves inoculating the cells with a viral sample and providing optimal conditions for viral growth and replication. As the virus multiplies within the host cells, observable changes, such as cytopathic effects, may occur. Cell culture allows for the identification and characterization of viruses, aiding in the development of diagnostic assays, vaccines, and antiviral drugs. Additionally, it facilitates the study of viral behavior, pathogenesis, and the evaluation of potential therapeutic interventions.

The passive prophylaxis segment is expected to have the highest CAGR during the forecast period

The passive prophylaxis segment is anticipated to have lucrative growth during the forecast period. Passive prophylaxis plays a pivotal role in the virology testing market, offering a complementary strategy alongside diagnostic testing to prevent and manage viral infections. In the context of virology testing, passive prophylaxis serves as a preventive measure for individuals at risk of exposure to specific viruses. The virology testing market benefits from the integration of passive prophylaxis by offering a comprehensive approach to viral infection management. Moreover, as the demand for effective antiviral solutions continues to grow, passive prophylaxis contributes to a multi-faceted strategy, enhancing the arsenal of tools available to healthcare professionals for both prevention and treatment.

Region with largest share:

North America commanded the largest market share during the extrapolated period due to the quick adoption of cutting-edge testing and diagnostic techniques, increased healthcare spending, the existence of supportive government regulations, the existence of cutting-edge clinical laboratories, and the existence of manufacturing firms. Another significant element boosting the market's expansion is the rise in R&D activity from both public and private institutions in the US.

Region with highest CAGR:

Asia Pacific is expected to witness profitable growth over the projection period, owing to significant growth and advancements in diagnostics and healthcare. The increasing awareness of healthcare, rising healthcare expenditures, and improvements in healthcare infrastructure drive the demand for virology testing. The Asia-Pacific region also experiences outbreaks of infectious diseases, necessitating efficient and rapid virology testing for early detection and containment. The growing emphasis on preventive healthcare and the implementation of public health initiatives further fuel the demand for virology testing solutions in this region.

Key players in the market:

Some of the key players in the Virology Testing Market include Bio-Rad Laboratories Inc, Abbot Healthcare, F. Hoffmann-La Roche AG, Fujirebio Diagnostics Inc. , Cepheid, Hologic Inc., Thermo Fisher Scientific Inc., Qiagen, bioMerieux SA, Siemens Healthineers, Diasorin, Trinity Biotech, Vircell, Biospherix, Ltd and Novogene Co Ltd.

Key Developments:

In August 2023, Abbott has partnered with Redcliffe Labs to launch Clinical Decision Support (CDS), also known as AlinIQ, which is powered by unique technologies such as Big Data Engines and Artificial Intelligence (AI).

In February 2022, Abbott, the global healthcare leader, announced new collaborations with key health-tech partners BeatO, Sugar.fit, PharmEasy, GOQii, 1MG, Zyla Health, Healthifyme and Fitterfly to usher a new era of holistic diabetes management care.

Product Types Covered:

• Assay Kits
• Instruments
• Consumables

Procedures Covered:

• Antigen Detection
• Cell Culture Method
• Specific Antibodies Detection
• Gene Sequencing
• Virus Nucleic Acid Detection
• Hemagglutination Assays

Diagnostic Techniques Covered:

• Immunoassay-based Method
• Mass Spectroscopy-based Method
• Molecular Diagnostics Method
• Other Diagnostic Techniques

Methods Covered:

• Passive Prophylaxis
• Active Prophylaxis
• Immunoprophylaxis
• Interferon's
• Antiviral Chemotherapy

Applications Covered:

• Respiratory Tract Infections
• Skin and Soft Tissue Infections
• Urinary Tract Infection
• GI Tract Infections
• Sexually Transmitted Diseases
• Eye Infections
• Perinatal Infections

End Users Covered:

• Clinics
• Hospitals
• Diagnostic Centers
• Laboratories
• Blood Banks
• Pharmacies

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Application Analysis
• 3.8 End User Analysis
• 3.9 Emerging Markets
• 3.10 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Virology Testing Market, By Product Type

• 5.1 Introduction
• 5.2 Assay Kits
• 5.3 Instruments
• 5.4 Consumables

6 Global Virology Testing Market, By Procedure

• 6.1 Introduction
• 6.2 Antigen Detection
• 6.3 Cell Culture Method
• 6.4 Specific Antibodies Detection
• 6.5 Gene Sequencing
• 6.6 Virus Nucleic Acid Detection
• 6.7 Hemagglutination Assays

7 Global Virology Testing Market, By Diagnostic Technique

• 7.1 Introduction
• 7.2 Immunoassay-based Method
• 7.3 Mass Spectroscopy-based Method
• 7.4 Molecular Diagnostics Method
  • 7.4.1 NGS-based methods
  • 7.4.2 PCR-based methods
• 7.5 Other Diagnostic Techniques

8 Global Virology Testing Market, By Method

• 8.1 Introduction
• 8.2 Passive Prophylaxis
• 8.3 Active Prophylaxis
• 8.4 Immunoprophylaxis
• 8.5 Interferon's
• 8.6 Antiviral Chemotherapy

9 Global Virology Testing Market, By Application

• 9.1 Introduction
• 9.2 Respiratory Tract Infections
• 9.3 Skin and Soft Tissue Infections
• 9.4 Urinary Tract Infection
• 9.5 GI Tract Infections
• 9.6 Sexually Transmitted Diseases
• 9.7 Eye Infections
• 9.8 Perinatal Infections

10 Global Virology Testing Market, By End User

• 10.1 Introduction
• 10.2 Clinics
• 10.3 Hospitals
• 10.4 Diagnostic Centers
• 10.5 Laboratories
• 10.6 Blood Banks
• 10.7 Pharmacies

11 Global Virology Testing Market, By Geography

• 11.1 Introduction
• 11.2 North America
  • 11.2.1 US
  • 11.2.2 Canada
  • 11.2.3 Mexico
• 11.3 Europe
  • 11.3.1 Germany
  • 11.3.2 UK
  • 11.3.3 Italy
  • 11.3.4 France
  • 11.3.5 Spain
  • 11.3.6 Rest of Europe
• 11.4 Asia Pacific
  • 11.4.1 Japan
  • 11.4.2 China
  • 11.4.3 India
  • 11.4.4 Australia
  • 11.4.5 New Zealand
  • 11.4.6 South Korea
  • 11.4.7 Rest of Asia Pacific
• 11.5 South America
  • 11.5.1 Argentina
  • 11.5.2 Brazil
  • 11.5.3 Chile
  • 11.5.4 Rest of South America
• 11.6 Middle East & Africa
  • 11.6.1 Saudi Arabia
  • 11.6.2 UAE
  • 11.6.3 Qatar
  • 11.6.4 South Africa
  • 11.6.5 Rest of Middle East & Africa

12 Key Developments

• 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 12.2 Acquisitions & Mergers
• 12.3 New Product Launch
• 12.4 Expansions
• 12.5 Other Key Strategies

13 Company Profiling

• 13.1 Bio-Rad Laboratories Inc
• 13.2 Abbot Healthcare
• 13.3 F. Hoffmann-La Roche AG
• 13.4 Fujirebio Diagnostics Inc.
• 13.5 Cepheid
• 13.6 Hologic Inc.
• 13.7 Thermo Fisher Scientific Inc.
• 13.8 Qiagen
• 13.9 bioMerieux SA
• 13.10 Siemens Healthineers
• 13.11 Diasorin
• 13.12 Trinity Biotech
• 13.13 Vircell
• 13.14 Biospherix, Ltd
• 13.15 Novogene Co Ltd.